Sanofi (NASDAQ:SNY) Sees Unusually-High Trading Volume on Earnings Beat

Sanofi (NASDAQ:SNY) shares saw strong trading volume on Friday following a better than expected earnings announcement. 5,696,313 shares traded hands during mid-day trading, an increase of 67% from the average daily volume of 3,414,580 shares. The stock last traded at $44.4260 and had previously closed at $43.13.

The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.29 billion. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. Sanofi’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 EPS.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported third-quarter adjusted earnings of $2.04 per share, well above the $1.56 analyst consensus, while revenue reached $17.25 billion versus expectations of $14.29 billion. Sales increased 16.2% year over year. Sanofi quarterly earnings report
• Positive Sentiment: Dupixent remained the key growth engine, generating approximately $6.36 billion in quarterly sales. The strong performance helped Sanofi raise its 2026 sales and business-earnings outlook, reinforcing investor confidence in near-term results. Sanofi Q3 earnings and outlook
• Positive Sentiment: Regeneron’s strong results, supported partly by its economics from the Dupixent partnership, provided an additional read-through on continued demand for the product and its contribution to Sanofi’s earnings. Regeneron earnings and Dupixent partnership
• Neutral Sentiment: Chief Executive Officer Paul Hudson is seeking acquisitions or other deals to replenish Sanofi’s pipeline ahead of Dupixent’s eventual patent expiration. Such transactions could support long-term growth, but also introduce execution and financial risks. Sanofi CEO pipeline strategy

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. DZ Bank reiterated a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. Berenberg Bank reissued a “buy” rating on shares of Sanofi in a report on Monday, October 5th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Hold” and an average price target of $49.50.

Institutional Investors Weigh In On Sanofi

Several hedge funds and other institutional investors have recently bought and sold shares of SNY. Pzena Investment Management LLC grew its position in Sanofi by 348.2% in the third quarter. Pzena Investment Management LLC now owns 113,396 shares of the company’s stock worth $4,675,000 after buying an additional 88,094 shares during the last quarter. Provenance Wealth Advisors LLC increased its holdings in shares of Sanofi by 359.8% in the third quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock valued at $96,000 after buying an additional 1,817 shares in the last quarter. Gallacher Capital Management LLC lifted its position in shares of Sanofi by 6.3% during the 3rd quarter. Gallacher Capital Management LLC now owns 6,777 shares of the company’s stock valued at $279,000 after acquiring an additional 402 shares during the last quarter. Signature Equity Partners LLC lifted its position in shares of Sanofi by 322.2% during the 3rd quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock valued at $35,000 after acquiring an additional 654 shares during the last quarter. Finally, Trek Financial LLC lifted its position in shares of Sanofi by 11.3% during the 3rd quarter. Trek Financial LLC now owns 6,852 shares of the company’s stock valued at $283,000 after acquiring an additional 696 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Trading Up 2.8%

The firm has a market capitalization of $107.50 billion, a P/E ratio of 21.95, a price-to-earnings-growth ratio of 1.37 and a beta of 0.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The firm has a 50 day moving average price of $42.21 and a two-hundred day moving average price of $44.35.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.